Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair initiated coverage on Applied Therapeutics Inc. (NASDAQ:APLT), a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.
William Blair對應用治療公司（Applied Therapeutics Inc.）（納斯達克：APLT）進行了覆蓋，該公司專注於罕見病，如半乳糖血症、SORD缺乏症和糖尿病心肌病的後期開發。
The analyst says, "Applied Therapeutics is an under-the-radar company developing a nice mix of therapeutics targeting rare diseases and some larger indications with potential for several major value inflections over the next 12 months."
分析師表示：“應用治療公司是一家低調開發罕見疾病和一些具有潛力的更大適應症的公司，未來12個月內可能出現幾個主要的價值影響。”
In April, the FDA extended the review period for Applied Therapeutics' marketing application, seeking approval for its potentially first marketed drug govorestat (AT-007) for Classic Galactosemia, by three months.
4月，FDA將針對應用治療公司的市場申請的審查期限延長了三個月，尋求批准其潛在的第一個市場推出的藥物govorestat（At-007）用於經典半乳糖血症。
William Blair anticipates that Applied Therapeutics will launch govorestat in the galactosemia market in 2025, predicting a successful rollout due to the high unmet medical need, absence of other approved therapies, well-identified patient population, and the strong performance of first-in-class rare disease products.
William Blair預測，由於高度不滿足的醫療需求、沒有其他獲批的療法、被識別的患者人口以及首創罕見疾病產品的強勁表現，應用治療公司將於2025年在半乳糖血症市場推出govorestat，並預測其成功推出。
The analyst estimates 2030 sales of govorestat to exceed $1 billion with 70% peak penetration in the galactosemia market.
該分析師估計，到2030年，govorestat的銷售額將超過10億美元，在半乳糖血症市場中達到70%的峯值滲透率。
The analyst initiates with an Outperform rating and estimates a fair value for shares of $14.
該分析師給予Outperform評級，並估計股票公允價值爲14美元。
Beyond govorestat, Applied Therapeutics is developing AT-001 (caficrestat) for diabetic cardiomyopathy.
除了govorestat外，應用治療公司還推出了At-001（caficrestat）用於糖尿病心肌病的開發。
Diabetic cardiomyopathy affects about 20% of diabetics and, accordingly, has blockbuster potential.
糖尿病心肌病影響約20％的糖尿病患者，因此具有巨大的潛力。
In February, Applied Therapeutics released interim 12-month results from the ongoing Phase 3 INSPIRE trial of oral govorestat in SORD deficiency patients, in which the primary and several key secondary endpoints were achieved.
2月份，應用治療公司發佈了正在進行的口服govorestat鈉鹽針對SORD缺乏症患者的III期INSPIRE試驗的中期12個月結果，在該試驗中，達到了主要和幾個關鍵的次要終點。
The Company expects that its cash and cash equivalents of $146.5 million as of March 31, 2024, will fund the business into 2026.
公司預計，截至2024年3月31日，其現金及現金等價物爲14650萬美元，將資助業務延續至2026年。
Price Action: APLT stock is up 18.70% at $5.91 at the last check on Wednesday.
最後檢查時，APLt股票上漲了18.70％，報5.91美元。
- After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial.
- 報告五例患者死亡後，數據委員會建議MacroGenics停止前列腺癌試驗。